New hope for tough-to-treat myelofibrosis: combo pill targets spleen swelling
NCT ID NCT06909136
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 30 times
Summary
This study tests a combination of two pills (WJ01024 and ruxolitinib) in about 33 adults with intermediate- or high-risk myelofibrosis whose spleen is enlarged and who didn't respond well to or couldn't tolerate previous JAK inhibitor treatment. The goal is to see if the combo is safe and can shrink the spleen and improve symptoms. The study has two phases: first finding the right dose, then testing how well it works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTERMEDIATE- AND HIGH-RISK MYELOFIBROSIS (MF) PATIENTS WITH SPLENOMEGALY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Henan Cancer Hospital
Zhengzhou, Zhengzhou, 450000, China
Conditions
Explore the condition pages connected to this study.